Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients

被引:44
作者
Zhang, Xiaoyan [1 ]
Hu, Yanyun [1 ]
Zeng, Hui [1 ]
Li, Lianxi [1 ]
Zhao, Jungong [2 ,3 ]
Zhao, Jun
Liu, Fang [1 ]
Bao, Yuqian [1 ]
Jia, Weiping [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6,Dept Endocrinol Metbol, Shanghai Clin Med Ctr Diabet,Shanghai Key Lab Dia, Shanghai Key Clin Ctr Metabol Dis,Inst Diabet, Shanghai 200030, Peoples R China
[2] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Intervent Radiol, Shanghai 200030, Peoples R China
[3] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Vasc Surg, Shanghai 200233, Peoples R China
来源
CARDIOVASCULAR DIABETOLOGY | 2015年 / 14卷
基金
美国国家科学基金会;
关键词
Fibroblast growth factor 21; Lower extremity atherosclerotic disease; Type; 2; diabetes; PERIPHERAL ARTERIAL-DISEASE; FATTY LIVER-DISEASE; METABOLIC PARAMETERS; FGF21; LEVELS; OBESITY; RISK; PREVALENCE; FGF-21;
D O I
10.1186/s12933-015-0190-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fibroblast growth factor 21 (FGF21) is an emerging metabolic regulator associated with glucose and lipid metabolism, and it is still unclear whether FGF21 is related to atherosclerosis. Here, we explored the potential link between FGF21 and lower extremity atherosclerotic disease (LEAD) in type 2 diabetic patients. Methods: A cross-sectional study was conducted on 504 type 2 diabetic patients (283 men, 221 women). LEAD was defined by Ankle-brachial index (ABI) < 0.9 and lower extremity arterial plaque evaluated by color Doppler ultrasound. Serum FGF21 concentrations were quantified by a sandwich enzyme-linked immunosorbent assay. Results: The total FGF21 levels of male and female patients had no significant differenence ((299.14(177.31-534.49) vs 362.50(214.01-578.73), P=0.516). Serum FGF21 levels in LEAD group were significantly higher than non-LEAD group in females (385.34(243.89-661.54) vs 313.13(156.38-485.79), P=0.006), while not in male patients (295.52(177.09-549.64) vs 342.09 (198.70-549.87), P=0.613). In diabetic women, subjects with LEAD had significantly higher serum FGF21 regardless of non-alcoholic fatty liver disease (NAFLD) (P < 0.05). And serum FGF21 levels were positively correlated with waist circumference and systolic blood pressure after adjusted for age and BMI (r=0.198, P=0.004; r=0.152, P=0.027; respectively). Moreover, FGF21 was independently tied to femoral intima-media thickness (FIMT) (beta=0.208, P=0.031). After adjusted for other LEAD risk factors, FGF21 was demonstrated to be an independent risk factor for LEAD in type 2 diabetic women (OR, 1.106; 95% CI 1.008-1.223; P=0.028). In addition, FGF21 was negatively correlated with estradiol in premenopausal diabetic women (r=-0.368, P=0.009). After adjusted for estradiol, serum FGF21 levels were still positively associated with FIMT in premenopausal diabetic women (r=0.381, P=0.007). In diabetic men, serum FGF21 levels were correlated with triglyceride and C-reactive protein even after adjusted for age and BMI (r=0.204, P=0.001; r=0.312, P < 0.001; respectively). However, serum FGF21 was not an independent impact factor for LEAD in men (P > 0.05). Conclusions: Serum FGF21 level independently and positively links LEAD in Chinese women with type 2 diabetes. The gender difference may be due to different estrogen levels.
引用
收藏
页数:9
相关论文
共 50 条
[21]   The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes [J].
He, Xingxing ;
Su, Jiaorong ;
Ma, Xiaojing ;
Lu, Wei ;
Zhu, Wei ;
Wang, Yufei ;
Bao, Yuqian ;
Zhou, Jian .
CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[22]   Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus [J].
Hu, Y. ;
Liu, J. ;
Zhang, H. ;
Xu, Y. ;
Hong, T. ;
Wang, G. .
DIABETES & METABOLISM, 2016, 42 (05) :358-363
[23]   Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease [J].
Miyazaki, Yoshichika ;
Saita, Emi ;
Kishimoto, Yoshimi ;
Ibe, Susumu ;
Seki, Toshiki ;
Miura, Kotaro ;
Suzuki-Sugihara, Norie ;
Ikegami, Yukinori ;
Ohmori, Reiko ;
Kondo, Kazuo ;
Momiyama, Yukihiko .
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (09) :821-828
[24]   Association between serum fibroblast growth factor 21 and diabetic nephropathy [J].
Jian, Wei-Xia ;
Peng, Wen-Hui ;
Jin, Jie ;
Chen, Xue-Ru ;
Fang, Wen-Jun ;
Wang, Wei-Xing ;
Qin, Li ;
Dong, Yan ;
Su, Qing .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2012, 61 (06) :853-859
[25]   Serum Levels of Fibroblast Growth Factor 21 Are Positively Associated with Aortic Stiffness in Patients with Type 2 Diabetes Mellitus [J].
Huang, Sin-Yi ;
Wu, Du-An ;
Tsai, Jen-Pi ;
Hsu, Bang-Gee .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (07)
[26]   The serum fibroblast growth factor 21 is correlated with retinopathy in patients with type 2 diabetes mellitus [J].
Heidari, Zahra ;
Hasanpour, Mahdieh .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (06)
[27]   Association of serum fibroblast growth factor 21 levels with skeletal muscle mass and mortality in chronic hemodialysis patients [J].
Chiu, Liang-Te ;
Wang, Chih-Hsien ;
Lin, Yu-Li ;
Hsu, Bang-Gee .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (12) :2481-2489
[28]   Serum Fibroblast Growth Factor 21 in Patients with and without Pterygia [J].
Yaghoobi, Gholamhosein ;
Shokoohi-Rad, Saeed ;
Jafarzadeh, Hamid ;
Abdollahi, Elham .
JOURNAL OF OPHTHALMIC & VISION RESEARCH, 2020, 15 (01) :38-44
[29]   Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors [J].
Chow, Wing Sun ;
Xu, Aimin ;
Woo, Yu Cho ;
Tso, Annette W. K. ;
Cheung, Stephen C. W. ;
Fong, Carol H. Y. ;
Tse, Hung Fat ;
Chau, Ming Tak ;
Cheung, Bernard M. Y. ;
Lam, Karen S. L. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (10) :2454-2459
[30]   Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus [J].
Taniguchi, Hirokazu ;
Nirengi, Shinsuke ;
Ishihara, Kengo ;
Sakane, Naoki .
PLOS ONE, 2022, 17 (02)